Merck KGaA agreed to buy Silence Therapeutics for cash at a 130% premium to its Oct. 16 closing price.

Merck KGaA agreed to acquire Silence Therapeutics for $1.85 billion, a 130% premium over its Oct. 16 closing price. The deal values Silence at $61 per share. Merck aims to strengthen its capabilities in treating rare diseases. Silence's Divesiran, a siRNA therapy for polycythemia vera, has FDA Fast Track and Orphan Drug designations.

Original reporting
Published Oct 19, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 12:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MRK
Relevance
9/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

High
01

Why it matters

The transaction provides immediate cash value to Silence shareholders and expands Merck's RNA therapeutic pipeline.

02

Market read

First disclosure of a major M&A deal in the biotech sector, likely to move both companies' stocks.

03

What to watch

Regulatory approvals for Divesiran and financing terms could affect deal completion.

Relevance 9/10Novelty 9/10Timing: today

Background

Merck KGaA announced a cash acquisition of Silence Therapeutics at a 130% premium to its prior closing price.

Market effects

Potential consolidation in biotech siRNA space, may boost peers developing RNA therapeutics.

European pharma M&A activity could see heightened interest.

Large cash deal may influence global biotech valuation multiples.

Counterpoint

Deal premium may be excessive; integration risk could pressure Merck KGaA's valuation.

Key entities

  • Merck KGaA

    German science and technology company operating in life science, healthcare, and electronics.

  • Silence Therapeutics

    Clinical-stage biotech developing siRNA therapies, including Divesiran for polycythemia vera.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.